동물용 의약품 시장 예측(-2034년) : 동물 유형, 제품 유형, 약제 클래스별, 투여 경로, 제형, 유통 채널, 치료 용도, 최종사용자, 처방 유형 및 지역별 세계 분석

According to Stratistics MRC, the Global Veterinary Pharmaceuticals Market is accounted for $58.5 billion in 2026 and is expected to reach $109.9 billion by 2034 growing at a CAGR of 8.2% during the forecast period. Veterinary pharmaceuticals encompass drugs, vaccines, and therapeutic products designed for the prevention, diagnosis, and treatment of diseases in animals. The market serves companion animals including dogs, cats, horses, birds, and other pets, as well as livestock animals including cattle, swine, poultry, sheep, goats, aquaculture species, and other farm animals. Product categories include anti-infectives, parasiticides, anti-inflammatory drugs, analgesics, vaccines, hormonal preparations, reproductive health products, nutritional therapeutics, sedatives and anesthetics, dermatological products, gastrointestinal drugs, cardiovascular drugs, respiratory drugs, and other therapeutic classes. Growing global meat consumption, rising pet ownership, increasing focus on animal health and welfare, and growing concerns about food safety and zoonotic diseases are key drivers of market expansion.

Market Dynamics:

Driver:

Rising global meat consumption and demand for livestock productivity

The increasing global demand for animal protein and livestock products is a primary driver for the veterinary pharmaceuticals market. Growing populations, rising incomes, and changing dietary patterns are driving meat, milk, and egg consumption, particularly in developing regions. Livestock producers are adopting veterinary health management practices to improve productivity, prevent disease outbreaks, and ensure food safety. Veterinary pharmaceuticals including vaccines, anti-infectives, and parasiticides are essential for maintaining herd health and production efficiency. The intensification of livestock production and growing awareness of animal disease impacts on productivity are driving pharmaceutical adoption across cattle, poultry, swine, and aquaculture sectors, sustaining strong market growth.

Restraint:

Regulatory complexities and approval timelines

The complex regulatory environment and lengthy approval processes for veterinary pharmaceuticals represent a major restraint for the market. Veterinary drugs require rigorous safety, efficacy, and quality testing before market authorization, with approval timelines varying across jurisdictions. Regulatory requirements for product registration, manufacturing standards, and labeling are extensive and resource-intensive. Changing regulations, including restrictions on antimicrobial use, require continuous adaptation. Compliance costs are significant, particularly for smaller manufacturers. These regulatory burdens may slow new product introductions, limit market access for certain products, and increase development costs, potentially constraining market growth.

Opportunity:

Growth in companion animal health spending

The increasing focus on companion animal health and rising pet care expenditure presents significant opportunities for veterinary pharmaceuticals market expansion. Pet owners are increasingly seeking advanced medical care for their animals, including preventive care, diagnostic services, and therapeutic treatments. The humanization of pets has led to greater willingness to invest in pharmaceuticals including vaccines, parasiticides, dermatological products, and chronic disease management. The growing pet population and rising disposable incomes are expanding the companion animal pharmaceutical market. As companion animal health spending continues increasing globally, pharmaceutical products for dogs, cats, and other pets capture growing market share.

Threat:

Antimicrobial resistance concerns and restrictions

Growing concerns about antimicrobial resistance and regulatory restrictions on veterinary antibiotic use pose significant threats to the veterinary pharmaceuticals market. Public health authorities are implementing stricter regulations on antimicrobial use in food-producing animals to preserve antibiotic effectiveness. Restrictions on certain antimicrobial classes limit treatment options and reduce market opportunities. Consumer demand for antibiotic-free meat products creates pressure for reduced antibiotic use in livestock production. These trends are forcing pharmaceutical companies to invest in alternatives and adapt product portfolios. The antimicrobial resistance threat may limit growth in the anti-infectives segment and require significant investment in new product development.

Covid-19 Impact:

The COVID-19 pandemic had a mixed impact on the veterinary pharmaceuticals market. Supply chain disruptions including raw material availability and logistics affected production and distribution. Livestock production continued as an essential industry, maintaining demand for veterinary pharmaceuticals. Companion animal pharmaceutical demand remained strong as pet ownership increased during lockdowns and veterinary services adapted with telemedicine. The pandemic highlighted the importance of animal health in food security and zoonotic disease prevention. Post-pandemic, the market has recovered strongly, with continued growth in companion animal spending, livestock production, and awareness of animal health importance.

The Livestock Animals segment is expected to be the largest during the forecast period

The Livestock Animals segment is expected to account for the largest market share during the forecast period, driven by the massive scale of food animal production, growing global meat and dairy consumption, and essential pharmaceutical needs in herd health management. Livestock animals including cattle, swine, poultry, sheep, goats, and aquaculture species represent large treatment populations requiring extensive pharmaceutical use. The segment benefits from the economic importance of livestock production, with productivity and disease management directly affecting producer profitability. Government animal disease control programs and veterinary services contribute to pharmaceutical consumption. As global protein demand continues rising, livestock animal pharmaceuticals maintain the largest market share.

The Vaccines segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Vaccines segment is predicted to witness the highest growth rate, fueled by increasing focus on disease prevention, growing concerns about zoonotic diseases, and expanding vaccine development for emerging and existing animal diseases. Vaccines are essential for preventing infectious diseases, reducing antibiotic use, and ensuring food safety in livestock production. The growing companion animal vaccination market is expanding with awareness of preventive healthcare benefits. Innovations in vaccine technology including recombinant vaccines, vectored vaccines, and DNA vaccines are expanding application possibilities. Increasing disease surveillance and government vaccination programs support adoption. As preventive healthcare continues gaining importance, vaccines deliver the fastest product segment growth.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, supported by advanced veterinary healthcare infrastructure, high livestock production standards, and significant companion animal health spending. The United States and Canada have well-established veterinary pharmaceutical industries with strong regulatory frameworks and extensive product availability. High livestock production with intensification drives pharmaceutical consumption. The region's high pet ownership rates and substantial companion animal spending support market growth. With advanced veterinary healthcare systems and high spending, North America maintains its dominant market position.

Region with highest CAGR:

Over the forecast period, the Asia-Pacific region is anticipated to exhibit the highest CAGR, driven by rising livestock production, growing meat consumption, expanding companion animal populations, and increasing focus on animal health across countries including China, India, Indonesia, and Southeast Asia. The region's large livestock production sectors create substantial pharmaceutical demand. Growing disposable incomes and urbanization are increasing companion animal ownership. Government veterinary service development and disease control programs support pharmaceutical adoption. Increasing awareness of animal health and welfare benefits and rising food safety standards drive market growth. As livestock production and companion animal populations continue expanding, Asia Pacific delivers the fastest veterinary pharmaceuticals market growth globally.

Key players in the market

Some of the key players in Veterinary Pharmaceuticals Market include Zoetis Inc., Merck Animal Health, Elanco Animal Health Incorporated, Boehringer Ingelheim Animal Health, Ceva Sante Animale, Virbac S.A., Vetoquinol S.A., Dechra Pharmaceuticals PLC, Phibro Animal Health Corporation, IDEXX Laboratories, Inc., Chanelle Pharma Group, Norbrook Laboratories Limited, HIPRA, Ourofino Saude Animal, Kyoritsu Seiyaku Corporation, Huvepharma AD, Indian Immunologicals Limited, and Ashish Life Science Pvt. Ltd.

Key Developments:

In June 2026, Elanco announced plans to establish Elanco Ventures, backed by a $25 million multi-year capital commitment to invest in next-generation therapeutics, digital health technologies, and One Health collaborative systems.

In June 2026, Merck Animal Health entered into a definitive agreement to acquire TARGAN Inc., a privately held poultry ag-tech innovator. The transaction integrates TARGAN's WingScan(TM) automated high-speed vision technology-which gender-sorts up to 160,000 chicks per hour-alongside Merck's comprehensive commercial respiratory and coccidiosis vaccine portfolio.

In May 2026, Boehringer Ingelheim partnered with the World Small Animal Veterinary Association (WSAVA) to publish a comprehensive global study mapping the "hidden impacts" of preventive veterinary care, highlighting that 87% of clinicians identify early-stage detection of subtle chronic pain as their most overlooked diagnostic role.

Animal Types Covered:

• Companion Animals
• Livestock Animals

Product Types Covered:

• Anti-Infectives
• Parasiticides
• Anti-Inflammatory Drugs
• Analgesics
• Vaccines
• Hormonal Preparations
• Reproductive Health Products
• Nutritional Therapeutics
• Sedatives and Anesthetics
• Dermatological Products
• Gastrointestinal Drugs
• Cardiovascular Drugs
• Respiratory Drugs
• Other Product Types

Drug Classes Covered:

• Antibiotics
• Antivirals
• Antifungals
• Antiparasitics
• NSAIDs
• Corticosteroids
• Endocrine Drugs
• Immunomodulators
• Biologics
• Other Drug Classes

Routes of Administration Covered:

• Oral
• Injectable
• Topical
• Intramammary
• Intranasal
• Ophthalmic
• Otic
• Other Routes of Administration

Dosage Forms Covered:

• Tablets
• Capsules
• Oral Solutions and Suspensions
• Powders
• Injectable Solutions
• Ointments and Creams
• Sprays
• Pour-On Formulations
• Boluses
• Premixes
• Other Dosage Forms

Distribution Channels Covered:

• Veterinary Hospitals
• Veterinary Clinics
• Retail Pharmacies
• Online Pharmacies
• Farm Supply Stores
• Veterinary Distributors
• Other Distribution Channels

Therapeutic Applications Covered:

• Infectious Diseases
• Parasitic Diseases
• Musculoskeletal Disorders
• Pain Management
• Dermatological Disorders
• Gastrointestinal Disorders
• Respiratory Disorders
• Reproductive Health
• Metabolic Disorders
• Cardiovascular Disorders
• Other Therapeutic Applications

End Users Covered:

• Veterinary Hospitals
• Veterinary Clinics
• Animal Farms
• Animal Shelters
• Research Institutes
• Homecare/Pet Owners

Prescription Types Covered:

• Prescription Medicines
• Over-the-Counter (OTC) Medicines

Regions Covered:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Netherlands
  • Belgium
  • Sweden
  • Switzerland
  • Poland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Malaysia
  • Singapore
  • Vietnam
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Colombia
  • Chile
  • Peru
  • Rest of South America
• Rest of the World (RoW)
  • Middle East
• Saudi Arabia
• United Arab Emirates
• Qatar
• Israel
• Rest of Middle East
  • Africa
• South Africa
• Egypt
• Morocco
• Rest of Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

• 1.1 Market Snapshot and Key Highlights
• 1.2 Growth Drivers, Challenges, and Opportunities
• 1.3 Competitive Landscape Overview
• 1.4 Strategic Insights and Recommendations

2 Research Framework

• 2.1 Study Objectives and Scope
• 2.2 Stakeholder Analysis
• 2.3 Research Assumptions and Limitations
• 2.4 Research Methodology
  • 2.4.1 Data Collection (Primary and Secondary)
  • 2.4.2 Data Modeling and Estimation Techniques
  • 2.4.3 Data Validation and Triangulation
  • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

• 3.1 Market Definition and Structure
• 3.2 Key Market Drivers
• 3.3 Market Restraints and Challenges
• 3.4 Growth Opportunities and Investment Hotspots
• 3.5 Industry Threats and Risk Assessment
• 3.6 Technology and Innovation Landscape
• 3.7 Emerging and High-Growth Markets
• 3.8 Regulatory and Policy Environment
• 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

• 4.1 Porter's Five Forces Analysis
  • 4.1.1 Supplier Bargaining Power
  • 4.1.2 Buyer Bargaining Power
  • 4.1.3 Threat of Substitutes
  • 4.1.4 Threat of New Entrants
  • 4.1.5 Competitive Rivalry
• 4.2 Market Share Analysis of Key Players
• 4.3 Product Benchmarking and Performance Comparison

5 Global Veterinary Pharmaceuticals Market, By Animal Type

• 5.1 Companion Animals
  • 5.1.1 Dogs
  • 5.1.2 Cats
  • 5.1.3 Horses
  • 5.1.4 Birds
  • 5.1.5 Other Companion Animals
• 5.2 Livestock Animals
  • 5.2.1 Cattle
  • 5.2.2 Swine
  • 5.2.3 Poultry
  • 5.2.4 Sheep
  • 5.2.5 Goats
  • 5.2.6 Aquaculture
  • 5.2.7 Other Livestock Animals

6 Global Veterinary Pharmaceuticals Market, By Product Type

• 6.1 Anti-Infectives
• 6.2 Parasiticides
• 6.3 Anti-Inflammatory Drugs
• 6.4 Analgesics
• 6.5 Vaccines
• 6.6 Hormonal Preparations
• 6.7 Reproductive Health Products
• 6.8 Nutritional Therapeutics
• 6.9 Sedatives and Anesthetics
• 6.10 Dermatological Products
• 6.11 Gastrointestinal Drugs
• 6.12 Cardiovascular Drugs
• 6.13 Respiratory Drugs
• 6.14 Other Product Types

7 Global Veterinary Pharmaceuticals Market, By Drug Class

• 7.1 Antibiotics
• 7.2 Antivirals
• 7.3 Antifungals
• 7.4 Antiparasitics
• 7.5 NSAIDs
• 7.6 Corticosteroids
• 7.7 Endocrine Drugs
• 7.8 Immunomodulators
• 7.9 Biologics
• 7.10 Other Drug Classes

8 Global Veterinary Pharmaceuticals Market, By Route of Administration

• 8.1 Oral
• 8.2 Injectable
• 8.3 Topical
• 8.4 Intramammary
• 8.5 Intranasal
• 8.6 Ophthalmic
• 8.7 Otic
• 8.8 Other Routes of Administration

9 Global Veterinary Pharmaceuticals Market, By Dosage Form

• 9.1 Tablets
• 9.2 Capsules
• 9.3 Oral Solutions and Suspensions
• 9.4 Powders
• 9.5 Injectable Solutions
• 9.6 Ointments and Creams
• 9.7 Sprays
• 9.8 Pour-On Formulations
• 9.9 Boluses
• 9.10 Premixes
• 9.11 Other Dosage Forms

10 Global Veterinary Pharmaceuticals Market, By Distribution Channel

• 10.1 Veterinary Hospitals
• 10.2 Veterinary Clinics
• 10.3 Retail Pharmacies
• 10.4 Online Pharmacies
• 10.5 Farm Supply Stores
• 10.6 Veterinary Distributors
• 10.7 Other Distribution Channels

11 Global Veterinary Pharmaceuticals Market, By Therapeutic Application

• 11.1 Infectious Diseases
• 11.2 Parasitic Diseases
• 11.3 Musculoskeletal Disorders
• 11.4 Pain Management
• 11.5 Dermatological Disorders
• 11.6 Gastrointestinal Disorders
• 11.7 Respiratory Disorders
• 11.8 Reproductive Health
• 11.9 Metabolic Disorders
• 11.10 Cardiovascular Disorders
• 11.11 Other Therapeutic Applications

12 Global Veterinary Pharmaceuticals Market, By End User

• 12.1 Veterinary Hospitals
• 12.2 Veterinary Clinics
• 12.3 Animal Farms
• 12.4 Animal Shelters
• 12.5 Research Institutes
• 12.6 Homecare/Pet Owners

13 Global Veterinary Pharmaceuticals Market, By Prescription Type

• 13.1 Prescription Medicines
• 13.2 Over-the-Counter (OTC) Medicines

14 Global Veterinary Pharmaceuticals Market, By Geography

• 14.1 North America
  • 14.1.1 United States
  • 14.1.2 Canada
  • 14.1.3 Mexico
• 14.2 Europe
  • 14.2.1 United Kingdom
  • 14.2.2 Germany
  • 14.2.3 France
  • 14.2.4 Italy
  • 14.2.5 Spain
  • 14.2.6 Netherlands
  • 14.2.7 Belgium
  • 14.2.8 Sweden
  • 14.2.9 Switzerland
  • 14.2.10 Poland
  • 14.2.11 Rest of Europe
• 14.3 Asia Pacific
  • 14.3.1 China
  • 14.3.2 Japan
  • 14.3.3 India
  • 14.3.4 South Korea
  • 14.3.5 Australia
  • 14.3.6 Indonesia
  • 14.3.7 Thailand
  • 14.3.8 Malaysia
  • 14.3.9 Singapore
  • 14.3.10 Vietnam
  • 14.3.11 Rest of Asia Pacific
• 14.4 South America
  • 14.4.1 Brazil
  • 14.4.2 Argentina
  • 14.4.3 Colombia
  • 14.4.4 Chile
  • 14.4.5 Peru
  • 14.4.6 Rest of South America
• 14.5 Rest of the World (RoW)
  • 14.5.1 Middle East
    • 14.5.1.1 Saudi Arabia
    • 14.5.1.2 United Arab Emirates
    • 14.5.1.3 Qatar
    • 14.5.1.4 Israel
    • 14.5.1.5 Rest of Middle East
  • 14.5.2 Africa
    • 14.5.2.1 South Africa
    • 14.5.2.2 Egypt
    • 14.5.2.3 Morocco
    • 14.5.2.4 Rest of Africa

15 Strategic Market Intelligence

• 15.1 Industry Value Network and Supply Chain Assessment
• 15.2 White-Space and Opportunity Mapping
• 15.3 Product Evolution and Market Life Cycle Analysis
• 15.4 Channel, Distributor, and Go-to-Market Assessment

16 Industry Developments and Strategic Initiatives

• 16.1 Mergers and Acquisitions
• 16.2 Partnerships, Alliances, and Joint Ventures
• 16.3 New Product Launches and Regulatory Approvals
• 16.4 Capacity Expansion and Investments
• 16.5 Other Strategic Initiatives

17 Company Profiles

• 17.1 Zoetis Inc.
• 17.2 Merck Animal Health
• 17.3 Elanco Animal Health Incorporated
• 17.4 Boehringer Ingelheim Animal Health
• 17.5 Ceva Sante Animale
• 17.6 Virbac S.A.
• 17.7 Vetoquinol S.A.
• 17.8 Dechra Pharmaceuticals PLC
• 17.9 Phibro Animal Health Corporation
• 17.10 IDEXX Laboratories, Inc.
• 17.11 Chanelle Pharma Group
• 17.12 Norbrook Laboratories Limited
• 17.13 HIPRA
• 17.14 Ourofino Saude Animal
• 17.15 Kyoritsu Seiyaku Corporation
• 17.16 Huvepharma AD
• 17.17 Indian Immunologicals Limited
• 17.18 Ashish Life Science Pvt. Ltd.